Clinical Trials Logo

Clinical Trial Summary

The main objective of the study is to evaluate the influence of caffeine intake on participants' energetic arousal, affect, motivation to achieve a training goal, satisfaction with training, and the sense of agency during training. Consequently, participants will engage in three sessions: caffeine, placebo, and no substance (in counterbalanced order). During each session, their affective and motivational states will be assessed, along with the performance of a standardized physical exercise test. The investigators hypothesize that participants who consume caffeine (caffeine condition) will exhibit higher levels of energy and motivation compared to the other two groups. Additionally, they are expected to experience greater optimism and expectancy regarding their training goals and achieve better results in the physical exercise test. A secondary aim of the study is to examine the impact of genetic variability on motivational and affective states of participants, as well as their performance in the physical exercise test after caffeine. The investigators will assess the CYP1A2 (-163C > A, rs762551; characterized such as "fast" (AA genotype) and "slow" caffeine metabolizers (C-carriers)) and ADORA2A (1976T > C; rs5751876; characterized by "high" (TT genotype) or "low" sensitivity to caffeine (C-carriers)).


Clinical Trial Description

Before participating in the study, participants will answer questions regarding their consumption of caffeinated beverages and the frequency of their workouts. They will also complete the Extreme Personality Scale measuring the tendency to pursue goals single-mindedly. Subsequently, they will be qualified for the study based on the questionnaire results and a brief interview. The study will involve the manipulation of energization through the administration of caffeine. Participants will take part in a randomized, crossover, double-blind study, where they will perform three identical training sessions after consuming: a) caffeine at a dose of 3 mg/kg of body weight; b) a placebo; and c) under control conditions (i.e., without substance administration). Capsule consumption will occur 60 minutes before the start of the training. Caffeine and placebo capsules will not differ in size, shape, color, and taste. As the effectiveness of caffeine use depends on the CYP1A2 (rs762551) and ADORA2 (rs5751876) gene polymorphisms, the study will also genotype these genes. The first gene is responsible for the rate of caffeine metabolism, determining whether people metabolize caffeine "fast" or "slow." The ADORA2A gene, encoding the adenosine A2A receptor, influences how "sensitive" people are to caffeine. DNA isolates obtained from oral epithelial cells collected from participants by qualified medical personnel will constitute the research material. Oral epithelial swabs will be collected directly from the participants into sterile tubes. Before and after substance intake (and additionally after the exercise test) participants will assess their arousal using the University of Wales Institute of Science and Technology Mood Adjective Checklist. Additionally, after substance intake and before exercise, participants will answer questions about motivation, affect and expectancy regarding training. Subsequently, participants will undergo training, taking the form of a supervised standardized exercise test. After exercise, participants will assess their satisfaction and feelings after completing the training. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06321861
Study type Interventional
Source Jagiellonian University
Contact Ewa Szumowska
Phone +48504756394
Email ewa.szumowska@uj.edu.pl
Status Recruiting
Phase N/A
Start date January 19, 2024
Completion date May 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT06038903 - The Turkish Version Of The Brief-Caffeine Expectancy Questionnaire
Completed NCT02900261 - Study on Sodium and Caffeine in Children and Adolescents
Completed NCT03850275 - The Effects of e+Shots Energy Beverage on Mental Energy N/A
Completed NCT01924481 - Effects of a Cocoa Shot on the Human Brain N/A
Completed NCT01330680 - Genetic Determinants of Cardiovascular Response to Coffee Drinking N/A
Completed NCT00184912 - The Effect of Caffeine on Ischemic Preconditioning N/A
Completed NCT03859882 - Protocol PERCAF 2018 N/A
Completed NCT02832401 - The Impact of Caffeine on Cognition in Schizophrenia N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Recruiting NCT05503732 - Effects of Energy Drinks on Sleep and Cardiovascular Health N/A
Not yet recruiting NCT05521386 - The Effects of Caffeine on Heart Rate and Heart Rate Variability N/A
Completed NCT06039358 - Effects of Caffeine Ingestion on the Biomechanics of Healthy Young Subjects N/A
Active, not recruiting NCT04547868 - Can Coffee/Caffeine Improve Post-Operative Gastrointestinal Recovery N/A
Completed NCT05559372 - Energy Drink Effects on Performance, Mood, and Cardiovascular Outcomes N/A
Completed NCT01783561 - Early Versus Routine Caffeine Administration in Extremely Preterm Neonates Phase 4
Completed NCT04852315 - Acute Caffeine Ingestion on Futsal Performance N/A
Completed NCT05975489 - Genetics in the Effect of Caffeine on Fat Oxidation N/A
Recruiting NCT03298347 - Caffeine for Preterm Infants With Apnea of Prematurity(AOP) N/A
Completed NCT01435486 - Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants N/A
Completed NCT04869176 - Effect of Caffeine on Heart Rate Variability in Newborns N/A